The primary objective of this study was to estimate 1) the annual risk of undergoing a severe hypoglycemic event in Italian patients with diabetes and 2) the risk of hospitalization following such event. From the HYPOTHESIS database, powered by 46 emergency departments covering a 12-million-odd population, data were extracted of 1,922 hypoglycemic events occurring in patients with diabetes in 2...

Background: Glybenclamide and metformin are two of the most common oral hypoglycemic drugs which are often used in treatment of type II diabetes mellitus. Toxicity due to these drugs may occur intentionally, accidentally, or even at the normal dosage because of the progression of such internal diseases as renal dysfunction. Methods: In this case series study, 59 patients poisoned with oral ...

BACKGROUND Hypoglycemic coma is a continuous threat for diabetic patients treated with insulin and/or oral hypoglycemic agents; it may be associated with substantial morbidity and mortality. METHODS We retrospectively reviewed our clinical experience with drug-induced hypoglycemic coma during a 7-year period. RESULTS The study consisted of 102 patients and included 61 females and 41 males. ...

OBJECTIVE Hypoglycemic treatments could modulate the risk for fractures in many ways. Most studies have not explored the effect on the incidence of bone fractures of individual oral hypoglycemic agents, rather all oral treatments as a whole. The aim of this case-control study, nested within a retrospective cohort, is the assessment of the risk for bone fractures associated with exposure to insu...

BACKGROUND Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA), an observational, non-interventional, 24-week post-marketing surveillance study in Japanese patients with type 2 diabetes (T2DM) having uncontrolled glycemic control, demonstrated that basal supported oral therapy (BOT) with insulin glargine was an effective and safe treatment in real-life clinical practice. We performed subgroup an...

Despite the development of effective pharmacological therapy to prevent both macrovascular and microvascular complications and adverse events, diabetes control remains sub-optimal. Poor adherence to recommended regimens is a causal factor in preventable morbidity and mortality in diabetic patients. Subgroups of patients with differing longitudinal profiles of adherence may yield differing treat...